Related Experiment Videos
Predictive properties of serum-prostate-specific antigen testing in a community-based setting
S J Jacobsen1, E J Bergstralh, H A Guess
1Section of Clinical Epidemiology, Mayo Clinic, Rochester, Minn, USA.
Archives of Internal Medicine
|November 25, 1996
Summary
Serum prostate-specific antigen (PSA) levels effectively detect prostate cancer in community settings. This population-based study shows PSA offers better discrimination than previously thought, improving screening accuracy.
Area of Science:
- Oncology
- Urology
- Epidemiology
Background:
- Previous studies on prostate-specific antigen (PSA) sensitivity/specificity were often in urology settings.
- Control groups in prior studies may have had higher PSA-elevating urologic conditions, biasing results.
- Population-based studies are needed to accurately assess PSA's screening utility.
Purpose of the Study:
- To determine the sensitivity and specificity of serum PSA levels for early prostate cancer detection.
- To evaluate PSA's effectiveness in a population-based screening context.
Main Methods:
- A population-based case-control study in Olmsted County, Minnesota.
- Included 177 newly diagnosed prostate cancer cases (age 50-79) with prediagnostic PSA.
- Control group comprised randomly selected men without prostate cancer.
Main Results:
- Median PSA was significantly higher in cases (9.4 ng/mL) vs. controls (1.2 ng/mL).
- Area under the ROC curve was 0.94, indicating strong discrimination.
- PSA's predictive power remained high even for clinically localized disease, outperforming previous estimates.
Conclusions:
- Serum PSA provides superior discrimination for prostate cancer in community settings compared to urologic practice-based studies.
- Previous decision analyses may have underestimated PSA's predictive value for primary care or community screening.
- PSA demonstrates significant potential for effective prostate cancer screening in the general population.